Recent advances in the diagnosis and management of primary myelofibrosis.

about

Recent advances in the diagnosis and management of primary myelofibrosis.

Item

http://www.wikidata.org/entity/Q54980872

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Recent advances in the diagnosis and management of primary myelofibrosis.

@en

Recent advances in the diagnosis and management of primary myelofibrosis.

@nl

type

Item

label

Recent advances in the diagnosis and management of primary myelofibrosis.

@en

Recent advances in the diagnosis and management of primary myelofibrosis.

@nl

prefLabel

Recent advances in the diagnosis and management of primary myelofibrosis.

@en

Recent advances in the diagnosis and management of primary myelofibrosis.

@nl

P1476

Recent advances in the diagnosis and management of primary myelofibrosis.

@en

P2093

Katsuto Takenaka

http://www.w3.org/2001/XMLSchema#string

Kazuya Shimoda

http://www.w3.org/2001/XMLSchema#string

Koichi Akashi

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

P304

679-690

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.3904/KJIM.2018.033

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2018-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2018-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29665657

http://www.w3.org/2001/XMLSchema#string

P921

myelofibrosis

P932

6030412

http://www.w3.org/2001/XMLSchema#string